HighTide Therapeutics and Quotient Sciences Announce Agreeme

Integrated Synthesis-to-Clinic Program Will Support HTD1801's Clinical Development and Regulatory Submission Package ROCKVILLE, Md., SHENZHEN, China and NOTTINGHAM, England, Dec. 15, 2022

Related Keywords

China , Shenzhen , Guangdong , Liping Liu , Kostenloser Wertpapierhandel , Mark Egerton , Prnewswire Hightide Therapeutics Inc , National Major New Drug Innovation Program , Drug Administration , Quotient Sciences , Clinical Development , Regulatory Submission , Mytide Therapeutics , Fast Track , Orphan Drug , National Major New Drug Innovation , Hightide , Herapeutics , Quotient , Ciences , Nnounce , Agreement , Conduct , Human , Dme , Program , Td1801 ,